What are the specific efficacy and functions of selumetinib/coceyu?

Selumetinib (Selumetinib) is a targeted oral small molecule MEK inhibitor that mainly blocks the abnormal proliferation signals of cancer cells by inhibiting the RAS/RAF/MEK/ERK signaling pathway, thereby exerting anti-tumor effects. The drug was developed by AstraZeneca and was originally used to treat non-resectable plexiform neurofibromatosis related to neurofibromatosis type 1 (NF1). It is currently approved for marketing in many countries around the world and is exploring its potential application in melanoma, thyroid cancer, lung cancer and other RAS mutated tumors.

The main mechanism of action of selumetinib is to selectively inhibitMEK1/2 kinase activity, thereby preventing the phosphorylation of downstream ERK, cutting off the growth signals of tumor cells, and causing abnormally proliferating cells to undergo apoptosis or growth arrest. In clinical practice, selumetinib is believed to be able to significantly reduce tumor volume, relieve pain, and improve activity limitation and quality of life in patients with NF1. In addition, some overseas studies have pointed out that selumetinib also shows the potential to inhibit tumor growth in some solid tumors carrying BRAF or KRAS mutations, especially when combined with other targeted drugs or immunotherapy. Due to its high selectivity, selumetinib is less toxic than traditional chemotherapy drugs, does not significantly inhibit bone marrow function, and is less likely to cause adverse reactions such as hair loss or severe nausea.

Currently, there are still a number of clinical studies on selumetinib underway around the world, focusing on its combined therapeutic value and exploration of resistance mechanisms in different cancer types, showing the broad prospects of this drug in the field of precision medicine. As an innovative MEK inhibitor, the application of selumetinib not only broadens new ideas for the treatment of neurofibromas and tumors, but also provides a more precise direction for targeted signaling pathway blocking therapy.

Reference materials:https://www.koselugo.com